NAD+ declines 50%+ between ages 20 and 60, impairing sirtuin activity, DNA repair, and mitochondrial function. Fisetin addresses the senescent cell accumulation that both drives and is driven by NAD+ decline. Together, these compounds address two of the most evidence-backed aging pathways through complementary mechanisms.

Does fisetin increase NAD+ directly?

Fisetin does not directly increase NAD+ levels. It reduces NAD+ consumption by eliminating senescent cells (which are high NAD+ consumers). The net effect may be a meaningful increase in cellular NAD+ availability.

Which should I prioritize: fisetin or NMN/NR?

Both address validated aging mechanisms. If budget is a constraint: fisetin senolytic protocol (monthly, 2 days) is relatively low cost compared to daily NMN/NR. Start with fisetin and add NMN/NR when budget allows.